Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05629052

TrEatment Approach in the Multimodal Era Registry

Sponsor: International CTEPH Association

View on ClinicalTrials.gov

Summary

The goal of this observational patient registry is to learn how expert centers treat patients with chronic thromboembolic pulmonary hypertension (CTEPH). CTEPH is a condition in which blood clots block the blood vessels in the lungs. There are currently three treatment options for patients with CTEPH: * surgery to remove blood clots from large vessels in the lungs (pulmonary endarterectomy (PEA)) * the use of a small balloon to unblock smaller blood vessels (balloon pulmonary angioplasty (BPA)) * drugs Patients can also receive a combination of these treatments. The main question this registry aims to answer are: * How many patients receive a given kind of treatment? * How do expert centers combine the different treatments? * Are patients doing better after they receive a given kind of treatment? * How many patients are alive 1, 3 and 5 years after they receive a given kind of treatment? Participants will receive the same treatments that they would receive if they did not participate in the study. During the study, patients will visit their doctors as they would do normally. The doctors will collect information on the patients' health and enter it into the study database. The follow-up time will be at least 3 years for all patients.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

1000

Start Date

2023-04-12

Completion Date

2028-04

Last Updated

2025-05-08

Healthy Volunteers

No

Interventions

PROCEDURE

Pulmonary endarterectomy

Surgical removal of a chronic clot from the pulmonary artery

PROCEDURE

Balloon pulmonary angioplasty

Catheter-based intervention to dilate occluded pulmonary vessels through the insertion and inflation of a small balloon

DRUG

Pulmonary hypertension (PH)-specific medication

Treatment with any PH-specific medication, i.e. endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, soluble guanylate cyclase stimulators, drugs acting on the prostanoid pathway and prostaglandin I2 receptor agonists

Locations (25)

University of California San Diego

San Diego, California, United States

Northwestern University

Evanston, Illinois, United States

Duke University

Durham, North Carolina, United States

UT Southwestern

Dallas, Texas, United States

Hospital Universitario Fundación Favaloro

Buenos Aires, Argentina

University Hospital Vienna

Vienna, Austria

University Hospitals Leuven

Leuven, Belgium

Santa Casa

Porto Alegre, Brazil

Toronto General Hospital

Toronto, Ontario, Canada

China-Japan Friendship Hospital

Beijing, China

Shaio Clinic Foundation

Bogotá, Colombia

General University Hospital

Prague, Czechia

Aarhus University Hospital

Aarhus, Denmark

Kerckhoff Clinic, Department of Thoracic Surgery

Bad Nauheim, Germany

Narayana Institute of Cardiac Science

Bangalore, India

University of Bologna

Bologna, Italy

Okayama Medical Center

Okayama, Japan

National Cerebral and Cardiovascular Center

Osaka, Japan

National Heart Institute

Mexico City, Mexico

Department of Cardiac and Vascular Diseases, John Paul II Hospital

Krakow, Poland

Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology, European Health Center Otwock

Otwock, Poland

National Heart Centre of Singapore

Singapore, Singapore

Pulmonary Hypertension Unit, Hospital 12 de Octubre

Madrid, Spain

Marmara University School of Medicine

Istanbul, Turkey (Türkiye)

Royal Papworth Hospital

Cambridge, United Kingdom